Articles tagged with: Deloitte

Three New Trustees Appointed

15th May 2014

Deloitte | Pinsent Masons | Purnells

Birmingham-based blood cancer charity Cure Leukaemia has announced a record-breaking 42% increase in their annual fundraising for the year ended October 31st 2013. The charity raised £863,474 last year, a figure that is worth over £8 million in potentially life saving...

Read the story >


Deloitte's Charity Luncheon raises nearly £5,000

10th March 2014

Deloitte

To coincide with International Women’s Day, Deloitte Birmingham staged a charity luncheon to support the work of Cure Leukaemia across the region. TV personality and successful businesswoman, Llewela Bailey had the audience in numerous bouts of laughter as she spoke over lunch, recalling...

Read the story >


Charity Partners visit Leukaemia Centre

29th January 2014

Deloitte | The Binding Site | Hotel Indigo

Last week staff from a number of Cure Leukaemia’s charity partners took time out from their normal working Friday to visit the Centre for Clinical Haematology at the Queen Elizabeth Hospital. The group included Sheila Newbury the Regional Corporate Responsibility Manager at Deloitte...

Read the story >


Deloitte backs Cure Leukaemia in 10th anniversary year

13th September 2013

Deloitte

Cure Leukaemia, has been selected as the charity partner for Deloitte in Birmingham in 2013/14. The leading business advisory firm, which employs over 600 people at its Birmingham office, is backing Cure Leukaemia’s vision to raise £10 million over the next 10 years. Deloitte joins a roster...

Read the story >


What we do

The Trials Acceleration Programme (TAP)

How funds raised for Cure Leukaemia help save lives

Cure Leukamia Pre footer image
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell
"Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies."

Sir John Bell